Treatment with lecanemab infusion was safe and generally well-tolerated within an outpatient memory clinic setting, with few infusion-related reactions and a low number of withdrawals due to ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early ...

Since receiving approval from the U.S. Food and Drug Administration in 2023 as only the second Alzheimer’s-modifying drug, sales of lecanemab, marketed as Leqembi, have consistently increased ...

Analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab (August 1, 2023, to October 1, 2024).

More than $100 million could be saved annually on discarded lecanemab (Leqembi), a simulation study suggested. Current vial sizes may result in 5.8% of the Alzheimer's disease drug being thrown ...

They found that indeed lecanemab was probably less effective in females than males in the Phase 3 trial. However, there was insufficient evidence to say the drug was totally ineffective in females.

Interim findings showed treatment with SC lecanemab resulted in 14% greater amyloid plaque removal in the brain at 6 months, assessed by amyloid positron emission tomography, compared with ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily ...

Lecanemab is the first of many drugs coming down the tracks. Each will have to be judged on its merits. But sometime soon it will be possible to give people the hope of treatment.

The development of the first drug in 30 years that modifies the disease - and not just the symptoms - of the most common form of dementia has given hope to patients. A global large-scale trial ...

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mil. Tuesday, 02 January 2024 12:17 GMT.